Toni Brand, PhD

TitlePostdoctoral Scholar
SchoolUCSF School of Medicine
Address1450 Third St
San Francisco CA 94158
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Brand T, Iida M, Corrigan KL, Braverman CM, Coan JP, Flanigan BG, Stein AP, Salgia R, Rolff J, Kimple RJ, Wheeler DL. The receptor tyrosine kinase AXL mediates nuclear translocation of the epidermal growth factor receptor. Sci Signal. 2017 Jan 03; 10(460). PMID: 28049763.
      View in: PubMed
    2. Brand T, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RC, Johnson DE, Grandis JR. Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients. Clin Cancer Res. 2017 Jun 15; 23(12):3072-3083. PMID: 27986750.
      View in: PubMed
    3. Iida M, Bahrar H, Brand T, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran PJ, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 Sep; 15(9):2175-86. PMID: 27422810; PMCID: PMC5010956 [Available on 03/01/17].
    4. Rodems TS, Iida M, Brand T, Pearson HE, Orbuch RA, Flanigan BG, Wheeler DL. Adaptive responses to antibody based therapy. Semin Cell Dev Biol. 2016 Feb; 50:153-63. PMID: 26808665.
      View in: PubMed
    5. Brand T, Iida M, Stein AP, Corrigan KL, Braverman CM, Coan JP, Pearson HE, Bahrar H, Fowler TL, Bednarz BP, Saha S, Yang D, Gill PS, Lingen MW, Saloura V, Villaflor VM, Salgia R, Kimple RJ, Wheeler DL. AXL Is a Logical Molecular Target in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Jun 01; 21(11):2601-12. PMID: 25767293; PMCID: PMC5032632.
    6. Iida M, Brand T, Starr MM, Huppert EJ, Luthar N, Bahrar H, Coan JP, Pearson HE, Salgia R, Wheeler DL. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy. Mol Cancer. 2014 Oct 24; 13:242. PMID: 25344208; PMCID: PMC4283113.
    7. Brand T, Iida M, Stein AP, Corrigan KL, Braverman CM, Luthar N, Toulany M, Gill PS, Salgia R, Kimple RJ, Wheeler DL. AXL mediates resistance to cetuximab therapy. Cancer Res. 2014 Sep 15; 74(18):5152-64. PMID: 25136066; PMCID: PMC4167493.
    8. Brand T, Iida M, Dunn EF, Luthar N, Kostopoulos KT, Corrigan KL, Wleklinski MJ, Yang D, Wisinski KB, Salgia R, Wheeler DL. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer. Mol Cancer Ther. 2014 May; 13(5):1356-68. PMID: 24634415; PMCID: PMC4013210.
    9. Rolle CE, Kanteti R, Surati M, Nandi S, Dhanasingh I, Yala S, Tretiakova M, Arif Q, Hembrough T, Brand T, Wheeler DL, Husain AN, Vokes EE, Bharti A, Salgia R. Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther. 2014 Mar; 13(3):576-84. PMID: 24327519; PMCID: PMC4286701.
    10. Iida M, Brand T, Starr MM, Li C, Huppert EJ, Luthar N, Pedersen MW, Horak ID, Kragh M, Wheeler DL. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct; 15(10):1196-206. PMID: 24204198; PMCID: PMC3819635.
    11. Li C, Brand T, Iida M, Huang S, Armstrong EA, van der Kogel A, Wheeler DL. Human epidermal growth factor receptor 3 (HER3) blockade with U3-1287/AMG888 enhances the efficacy of radiation therapy in lung and head and neck carcinoma. Discov Med. 2013 Sep; 16(87):79-92. PMID: 23998444; PMCID: PMC3901945.
    12. Brand T, Iida M, Luthar N, Wleklinski MJ, Starr MM, Wheeler DL. Mapping C-terminal transactivation domains of the nuclear HER family receptor tyrosine kinase HER3. PLoS One. 2013; 8(8):e71518. PMID: 23951180; PMCID: PMC3738522.
    13. Brand T, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 2013 Sep; 108(3):370-7. PMID: 23830194; PMCID: PMC3818450.
    14. Iida M, Brand T, Campbell DA, Starr MM, Luthar N, Traynor AM, Wheeler DL. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biol Ther. 2013 Jun; 14(6):481-91. PMID: 23760490; PMCID: PMC3813564.
    15. Kawada I, Hasina R, Lennon FE, Bindokas VP, Usatyuk P, Tan YH, Krishnaswamy S, Arif Q, Carey G, Hseu RD, Robinson M, Tretiakova M, Brand T, Iida M, Ferguson MK, Wheeler DL, Husain AN, Natarajan V, Vokes EE, Singleton PA, Salgia R. Paxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancer. Cancer Biol Ther. 2013 Jul; 14(7):679-91. PMID: 23792636; PMCID: PMC3742497.
    16. Traynor AM, Weigel TL, Oettel KR, Yang DT, Zhang C, Kim K, Salgia R, Iida M, Brand T, Hoang T, Campbell TC, Hernan HR, Wheeler DL. Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer. Lung Cancer. 2013 Jul; 81(1):138-41. PMID: 23628526; PMCID: PMC3679338.
    17. Brand T, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small GTPases. 2012 Jan-Mar; 3(1):34-9. PMID: 22714415; PMCID: PMC3398915.
    18. Brand T, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med. 2011 Nov; 12(66):419-32. PMID: 22127113; PMCID: PMC3305885.
    19. Brand T, Dunn EF, Iida M, Myers RA, Kostopoulos KT, Li C, Peet CR, Wheeler DL. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab. Cancer Biol Ther. 2011 Sep 01; 12(5):436-46. PMID: 21725209; PMCID: PMC3219082.
    20. Brand T, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 01; 11(9):777-92. PMID: 21293176; PMCID: PMC3100630.
    21. Brand T, Wheeler DL. Treating PIK3CA and EGFR overexpressing breast cancers with lithium citrate. Cancer Biol Ther. 2011 Feb 01; 11(3):368-70. PMID: 21228636.
      View in: PubMed
    Back to TOP